Aytu BioPharma, Inc.

符号: AYTU

NASDAQ

2.9043

USD

今天的市场价格

-0.9631
市盈率
-0.0159
PEG比率
16.17M
MRK市值
0.00%
DIV收益率

Aytu BioPharma, Inc. (AYTU) 财务报表

Q: 什么是 Aytu BioPharma, Inc. (AYTU) 总资产是多少？

Aytu BioPharma, Inc. (AYTU) 总资产为 .

Download

年度季度

线性对数

在图表中，您可以看到的动态默认数字 Aytu BioPharma, Inc. (AYTU). 的默认数据。公司收入显示 18.495 M 的平均值，即 4.353 % 增长率。整个期间的平均毛利润为 10.507 M，即 4.013 %. 平均毛利率为 2.170 %. 公司去年的净收入增长率为 -0.845 %，等于 -11.026 % % 整个公司历史的平均增长率.,

年度季度

10Y 20Y 30Y 40Y

资产负债表

深入分析 Aytu BioPharma, Inc. 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为，反映了公司的高点和低点。与季度相比，这一数字调整为0. 回顾过去一年，总资产变化为 -0.008. 在流动资产领域，AYTU 的报告货币为72.832. 这些资产中的很大一部分，即 22.985 是现金和短期投资。与去年的数据相比，该部分的变化率为0.187%. 公司的债务概况显示，以报告货币计算的长期债务总额为 14.713. 这一数字表明，-0.100% 的年同比变化. 股东权益总额所体现的股东价值是以报告货币计算的 39.357. 这方面的年同比变化率为 -0.146%. 深入了解公司财务信息后，会发现更多细节。应收账款净额的估值为28.937，存货估值为 11.99，商誉估值为 0（如有. 无形资产总额（如果有）按 58.97 估值.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008
balance-sheet.row.cash-and-short-term-investments	81.66	23	19.4	49.6	48.1	11	7	0.8	9.1	7.4	2.6	0	0	0	0	0	0	0
balance-sheet.row.short-term-investments	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
balance-sheet.row.net-receivables	122.27	28.9	21.7	28.2	5.2	1.7	0.6	0.5	0.2	0.2	0	0	0	0	0	0	0	0
balance-sheet.row.inventory	51.6	12	10.8	16.3	10	1.4	1.3	1.3	0.5	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-current-assets	4.13	0.9	0.6	1	5.7	1.2	0.5	0.4	0.3	0.5	0.7	0	0	0	0	0	0	0
balance-sheet.row.total-current-assets	293.27	72.8	59.9	105.2	75	15.4	9.5	3	10.1	8.1	3.3	0	0	0	0	0	0	0
balance-sheet.row.property-plant-equipment-net	15.7	3.9	6.3	8.7	0.9	0.2	0.2	0.6	0.2	0	0.1	0	0	0	0	0	0	0
balance-sheet.row.goodwill	0	0	0	65.8	28.1	0	0	0.2	0.2	0.1	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	235.49	59	70.6	85.5	48.9	19.1	11.4	11.1	13.6	9.7	8.2	0.8	0	0	0	0	0	0
balance-sheet.row.goodwill-and-intangible-assets	235.49	59	70.6	151.3	76.9	19.1	11.4	11.3	13.8	9.8	8.2	0.8	0	0	0	0	0	0
balance-sheet.row.long-term-investments	-1.38	-1.4	0	-10.9	-1.8	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.tax-assets	1.38	1.4	0	10.9	1.8	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-non-current-assets	3.36	0.8	0.8	0.5	0	0	0	0	0.2	0.3	0.5	-0.8	0	0	0	0	0	0
balance-sheet.row.total-non-current-assets	254.55	63.6	77.7	160.4	77.9	19.3	11.6	12	14.2	10.1	8.7	0	0	0	0	0	0	0
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	547.82	136.5	137.6	265.7	152.8	34.7	21.1	15	24.3	18.2	12	0	0	0	0	0	0.1	0.1
balance-sheet.row.account-payables	53.09	13.5	11	19.3	11.8	2.3	2.1	2.2	3.5	1.2	0.6	0	0	0	0	0	0	0
balance-sheet.row.short-term-debt	17.7	1.6	3.9	25.5	1.3	0	0	0	0	0	4.6	0.1	0.1	0.1	0.1	0.1	0	0
balance-sheet.row.tax-payables	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.long-term-debt-total	55.92	14.7	14.3	2.8	0.7	0	0	0	0	-0.4	0	0	0	0	0	0	0	0
Deferred Revenue Non Current	-1.38	-1.4	0	-11.2	-1.8	0	0	0	0	0.4	0	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	1.38	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	82.35	7.1	49.5	7.4	14.9	3.1	1.3	1.4	6.6	0.2	0.8	0	0	0	0	0	0	0
balance-sheet.row.total-non-current-liabilities	118.45	28.1	27.1	18.7	29.5	22.3	4.2	7.4	4.2	1.1	0.6	0	0.1	0.1	0.1	0.1	0	0
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0	-0.1	-0.1	-0.1	-0.1	0	0
balance-sheet.row.capital-lease-obligations	4.05	0.8	2.2	3.6	1	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	402.53	97.1	91.5	128.1	57.8	27.6	7.6	11	14.3	2.6	6.6	0.1	0.1	0.1	0.1	0.1	0	0
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0	0.2	0
balance-sheet.row.retained-earnings	-1230.52	-304.1	-288.5	-178.3	-120	-106.4	-79.3	-69.1	-46.6	-18.4	-10.7	-0.6	0	0	0	-0.3	-0.2	-0.1
balance-sheet.row.accumulated-other-comprehensive-income-loss	0	0	0	0	0	0	0	-0.2	-0.1	-5	0	10.5	-0.5	-0.5	-0.3	0	0	0
balance-sheet.row.other-total-stockholders-equity	1375.81	343.5	334.6	315.9	215	113.5	92.7	73.3	56.8	39	16.1	-10.4	0.4	0.4	0.3	0.2	0	0.2
balance-sheet.row.total-stockholders-equity	145.29	39.4	46.1	137.6	95	7.1	13.4	4	10.1	15.6	5.4	-0.1	-0.1	0	-0.1	0	0	0
balance-sheet.row.total-liabilities-and-stockholders-equity	547.82	136.5	137.6	265.7	152.8	34.7	21.1	15	24.3	18.2	12	0	0	0	0	0	0.1	0.1
balance-sheet.row.minority-interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-equity	145.29	39.4	46.1	137.6	95	7.1	13.4	4	10.1	15.6	5.4	-0.1	-0.1	0	-0.1	0	0	0
balance-sheet.row.total-liabilities-and-total-equity	547.82	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	-1.38	-1.4	0	-10.9	-1.8	0	0	0	1	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-debt	73.62	16.4	18.2	28.3	2	0	0	0	0	0	4.6	0.1	0.1	0.1	0.1	0.1	0	0
balance-sheet.row.net-debt	-8.04	-6.6	-1.2	-21.3	-46.1	-11	-7	-0.8	-8.1	-7.4	2	0.1	0.1	0	0.1	0	0	0

现金流量表

在 Aytu BioPharma, Inc. 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 0.822 的转变。该公司最近通过发行 15.57 扩大了股本，与上一年相比出现了-75.000 的差异. 有趣的是，公司的部分股票，特别是 0，是由公司自己回购的。这一举动导致0.000 比上一年有所变化。同时，以报告货币计算，公司的应付账款目前为 2.38. 公司的投资活动产生了现金使用净额，按报告货币计算达到-117000.000. 与上一年相比， -0.964 发生了变化. 在同一时期，公司记录了 8.81, -0.11 和 -2.35，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为0.000，同比差异为0.000. 此外，公司还将0 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 -4.36，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008
cash-flows.row.net-income	-18	-17.1	-110.2	-58.3	-13.6	-27.1	-10.2	-22.5	-28.2	-7.7	-5.6	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1
cash-flows.row.depreciation-and-amortization	8.72	8.8	10.3	9.2	6.2	2.7	2.6	4.4	0.9	0.1	0.1	0	0	0	0	0	0
cash-flows.row.deferred-income-tax	7.31	3.3	0	22.3	0.6	-0.1	-1.9	1.6	13.5	0	-0.8	0	0	0.1	0	0	0
cash-flows.row.stock-based-compensation	3.55	6	5.2	3.6	1.1	1	0.3	2.5	0.9	1	0.5	0	0	0.1	0	0	0
cash-flows.row.change-in-working-capital	1.71	-5.8	-10.9	1.7	-12.6	-0.2	-0.7	-1	1.8	-0.1	0.3	0	0	0	0	0	0
cash-flows.row.account-receivables	-3.79	-7.2	6.5	1.5	-3.6	-1.2	-0.1	-0.4	0	-0.2	0	0	0	0	0	0	0
cash-flows.row.inventory	-2.57	-3.6	1.3	2.8	-7	-0.1	0	0.2	-0.5	0	0	0	0	0	0	0	0
cash-flows.row.account-payables	0.19	2.4	-7.7	-3.2	-1.4	0.1	-0.1	0.5	1.6	0.5	0.4	0	0	0	0	0	0
cash-flows.row.other-working-capital	7.87	2.6	-11	0.6	-0.7	0.9	-0.5	-1.4	0.7	-0.5	-0.2	-0.1	0	0	0	0	0
cash-flows.row.other-non-cash-items	2.81	-0.4	76.7	-4.5	-10	9.8	-6	1.2	0.4	0.1	0	0	0	-0.1	0	0	0
cash-flows.row.net-cash-provided-by-operating-activities	6.11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	0	0	0	-2.3	0	-0.1	-0.1	-0.1	-2.3	0	0	0	0	0	0	0	0
cash-flows.row.acquisitions-net	0	0	-3.2	-2.8	0.2	-0.5	0	-4	-3.1	-1	0	0	0	0	0	0	0
cash-flows.row.purchases-of-investments	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0
cash-flows.row.sales-maturities-of-investments	0	0	0	0	0	0	0	-0.1	0	0	0	0	0	0	0	0	0
cash-flows.row.other-investing-activites	-0.4	-0.1	-0.1	2.4	-5.8	-0.5	-0.4	0.6	0	0	0	0	0	0	0	0	0
cash-flows.row.net-cash-used-for-investing-activites	-0.4	-0.1	-3.2	-2.8	-5.7	-1.1	-0.5	-3.5	-5.3	-1	0	0	0	0	0	0	0
cash-flows.row.debt-repayment	-2.39	-2.3	-172.5	-54.9	-19.4	-5	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-issued	3.93	15.6	11.7	45.1	0	0	0.2	9.3	12.7	5	0	0	0	0	0	0	0.1
cash-flows.row.common-stock-repurchased	0	0	0	0	0	0	0	0	-0.9	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-financing-activites	-7.22	-4.4	162.3	40.2	90.5	24.1	22.4	0.8	4.8	7.4	5.2	0	0	0	0	0	0
cash-flows.row.net-cash-used-provided-by-financing-activities	-5.68	8.9	1.5	30.3	71.1	19.1	22.7	10.2	16.7	12.4	5.2	0	0	0.1	0	0	0.1
cash-flows.row.effect-of-forex-changes-on-cash	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.net-change-in-cash	0.03	3.6	-30.5	1.6	37	4.2	6.2	-7.2	0.7	4.7	-0.3	0	0	0	0	0	0
cash-flows.row.cash-at-end-of-period	81.66	23	19.4	49.9	48.3	11.3	7.1	0.9	8.1	7.4	2.6	0	0	0	0	0	0
cash-flows.row.cash-at-beginning-of-period	81.63	19.4	49.9	48.3	11.3	7.1	0.9	8.1	7.4	2.6	2.9	0	0	0	0	0	0
cash-flows.row.operating-cash-flow	6.11	-5.1	-28.8	-26	-28.4	-13.8	-15.9	-13.8	-10.7	-6.6	-5.5	0	0	-0.1	0	0	0
cash-flows.row.capital-expenditure	0	0	0	-2.3	0	-0.1	-0.1	-0.1	-2.3	0	0	0	0	0	0	0	0
cash-flows.row.free-cash-flow	6.11	-5.1	-28.8	-28.3	-28.4	-13.9	-16	-13.9	-12.9	-6.6	-5.5	0	0	-0.1	0	0	-0.1

利润表行

Aytu BioPharma, Inc. 的收入与上期相比变化了 0.111%。据报告, AYTU 的毛利润为 66.63。该公司的营业费用为 78.96，与上年相比变化了 -10.663%. 折旧和摊销费用为 8.81，与上一会计期间相比变化了 0.177%. 营业费用报告为 78.96，显示-10.663% 的同比变化。销售和营销费用为 0, 其中 0.000% 与上年相比发生了变化。基于近期数据的EBITDA为 0，同比增长-1.459%. 营业收入为 -17.07，与上年相比变化了-1.459%. 净利润的变化率为 -0.845%。去年的净收入为-17.05.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008
income-statement-row.row.total-revenue	98.5	107.4	96.7	65.6	27.6	7.3	3.7	3.2	2.6	0.3	0.1	0	0	0	0	0	0	0
income-statement-row.row.cost-of-revenue	36.2	40.8	44.4	36.4	7.6	2.2	2.1	1.4	1	0.1	0	0	0	0	0	0	0	0
income-statement-row.row.gross-profit	62.29	66.6	52.3	29.2	20.1	5.1	1.6	1.8	1.6	0.2	0.1	0.1	0	0	0	0	0	0
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	2.45	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	25.68	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	34.78	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	-1.94	-4.8	4.1	6	4.5	2.1	6.3	1.7	0.7	0	0	0	0	0	0	0	0	0
income-statement-row.row.operating-expenses	65.31	79	88.4	67.4	41	22	19.5	20.7	15.8	7.8	6.4	0.1	0.1	0.1	0.1	0.1	0.1	0
income-statement-row.row.cost-and-expenses	101.52	119.7	132.8	103.9	48.6	24.2	21.5	22.1	16.8	7.9	6.4	0.1	0.1	0.1	0.1	0.1	0.1	0
income-statement-row.row.interest-income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.interest-expense	-3.86	0	147.5	0	0	0	0.7	2.5	5.5	0.1	0	0	0	0	0	0	0	0
income-statement-row.row.selling-and-marketing-expenses	34.78	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	-11.55	-4.7	-147.5	-19.8	7.3	-10.3	8.4	-1.1	-8.5	-0.1	0	0	0	0	0	0	0	0
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	-1.94	-4.8	4.1	6	4.5	2.1	6.3	1.7	0.7	0	0	0	0	0	0	0	0	0
income-statement-row.row.total-operating-expenses	-11.55	-4.7	-147.5	-19.8	7.3	-10.3	8.4	-1.1	-8.5	-0.1	0	0	0	0	0	0	0	0
income-statement-row.row.interest-expense	-3.86	0	147.5	0	0	0	0.7	2.5	5.5	0.1	0	0	0	0	0	0	0	0
income-statement-row.row.depreciation-and-amortization	5.71	4.8	4.1	23.7	-3.7	12.5	2.6	4.4	0.9	0.1	0.1	0	0	0	0	0	0	0
income-statement-row.row.ebitda-caps	-0.31	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	-8.26	-17.1	37.2	-38.2	-20.9	-16.8	-19.7	-20.1	-21.7	-7.6	-6.3	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	0
income-statement-row.row.income-before-tax	-17.17	-17.1	-110.3	-58	-13.6	-27.1	-10.2	-22.5	-28.2	-7.7	-6.4	-0.1	-0.1	-0.1	-0.1	-0.1	0	0
income-statement-row.row.income-tax-expense	1.25	-0.1	-0.1	0.3	-9.9	20	-2.1	1.1	8.5	0	-0.8	0.9	0	0	0	0	0	0
income-statement-row.row.net-income	-16.64	-17.1	-110.2	-58.3	-3.7	-47.2	-10.2	-22.5	-28.2	-7.7	-5.6	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	0